EUVIMEDEUVIMED entdecken
Leserbrief

Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310

Luke J Laffin, Stephen J Nicholls, Russell S Scott, Peter M Clifton, Renate Koops, Ashish Sarraju iD, Shweta Singh, Qiuqing Wang, Kathy Wolski, Huansheng Xu, Jen Nielsen, Naimish Patel und 2 weitere

New England Journal of Medicine · 01.10.2026 · 395 (13) · 1343-1345

DOI: 10.1056/nejmc2609825 ↗

Kurz gefasst

Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 01.10.2026. Verfasst von Luke J Laffin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Coordinating Center for Clinical Research, Cleveland. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 4 Literaturangaben. Gefördert von: CRISPR Therapeutics.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a phase 1a trial, one-time CRISPR-Cas9 gene editing with CTX310 was associated with no treatment-related dose-limiting toxic effects and with sustained reductions in ANGPTL3 and atherogenic lipids at 1 year.

Autor:innen und Institutionen

  • Cleveland Clinic Coordinating Center for Clinical Research, Cleveland.
  • Victorian Heart Institute, Melbourne, VIC, Australia.
  • New Zealand Clinical Research, Christchurch, New Zealand.
  • Royal Adelaide Hospital, Adelaide, SA, Australia.
  • Aotearoa Clinical Trials, Auckland, New Zealand.
  • CRISPR Therapeutics, Boston.

ORCID-Profile: Ashish Sarraju, Steven E Nissen

Förderung

  • CRISPR Therapeutics

Zitieren

APA

Laffin, L. J., Nicholls, S. J., Scott, R. S., Clifton, P. M., Koops, R., Sarraju, A., Singh, S., Wang, Q., Wolski, K., Xu, H., Nielsen, J., Patel, N., Duran, J. M., & Nissen, S. E. (2026). Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310. New England Journal of Medicine, 395(13), 1343-1345. https://doi.org/10.1056/nejmc2609825

Vancouver

Laffin LJ, Nicholls SJ, Scott RS, Clifton PM, Koops R, Sarraju A, et al. Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310. New England Journal of Medicine. 2026;395(13):1343-1345. doi:10.1056/nejmc2609825

BibTeX
@article{Laffin2026,
  author = {Laffin, Luke J and Nicholls, Stephen J and Scott, Russell S and Clifton, Peter M and Koops, Renate and Sarraju, Ashish and Singh, Shweta and Wang, Qiuqing and Wolski, Kathy and Xu, Huansheng and Nielsen, Jen and Patel, Naimish and Duran, Jason M and Nissen, Steven E},
  title = {Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {13},
  pages = {1343--1345},
  doi = {10.1056/nejmc2609825}
}
Kostenlos starten →